Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice

Get up to date on the latest advances on incorporating CD38 antibodies into treatment regimens for multiple myeloma to improve outcomes and consider strategies for how to provide more equitable access to high-quality multiple myeloma care with downloadable slides and an on-demand webcast from a workshop series.

Share

Program Content

Activities

CD38 Antibodies in MM
Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 25, 2023

Activities

CD38 Antibodies in MM
Expert Guidance for Clinical Practice: Implementing CD38 Antibodies for Multiple Myeloma
Video
Congratulations: You achieved a completion on 04/09/2022

Released: January 04, 2024

Expires: January 03, 2025

Faculty

cover img faculity

Ajai Chari, MD

Director of Multiple Myeloma Program
Professor of Clinical Medicine
University of California- San Francisco
San Francisco, California

cover img faculity

Saad Z. Usmani, MD, MBA, FACP

Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Professor
Weill Cornell Medical College, Cornell University
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Sanofi.

Sanofi